|
gptkbp:instanceOf
|
gptkb:brand
gptkb:drug
|
|
gptkbp:activeIngredient
|
gptkb:tirzepatide
|
|
gptkbp:approvalYear
|
2022
|
|
gptkbp:associatedWith
|
gptkb:Ozempic
gptkb:Rybelsus
gptkb:Wegovy
gptkb:Trulicity
|
|
gptkbp:ATCCode
|
A10BK04
|
|
gptkbp:chemicalClass
|
peptide
|
|
gptkbp:contraindication
|
gptkb:medullary_thyroid_carcinoma
gptkb:multiple_endocrine_neoplasia_syndrome_type_2
|
|
gptkbp:developedBy
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:form
|
solution for injection
pre-filled pen
|
|
gptkbp:genericAvailable
|
no
|
|
gptkbp:halfLife
|
about 5 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Mounjaro
|
|
gptkbp:indication
|
gptkb:type_2_diabetes
weight management
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:marketedIn
|
gptkb:Europe
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
GIP receptor agonist
GLP-1 receptor agonist
|
|
gptkbp:notRecommendedFor
|
type 1 diabetes
pediatric patients
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:prescribes
|
healthcare professionals
|
|
gptkbp:prescriptionRequired
|
yes
|
|
gptkbp:riskFactor
|
pancreatitis
allergic reactions
hypoglycemia (when used with insulin or sulfonylureas)
gastrointestinal disorders
|
|
gptkbp:routeOfAdministration
|
subcutaneous injection
|
|
gptkbp:sideEffect
|
nausea
vomiting
diarrhea
constipation
indigestion
decreased appetite
|
|
gptkbp:status
|
FDA approved
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:usedFor
|
weight loss
blood sugar control
|
|
gptkbp:website
|
https://www.mounjaro.com/
|
|
gptkbp:bfsParent
|
gptkb:礼来公司
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:bfsLayer
|
5
|